SV

Street Verdict

Analyst Scorecard

RUBICON · NSE

Rubicon Research Limited

₹1,718.7

-0.21% (-₹3.6)

Prev. close

₹1,722.3

Volume

2,41,875

Delivery %

65.8%

As of

20 Nov 2026

Price history

₹1,718.7-₹85.4 (-4.73%) · 3M
18 Aug 2026 → 20 Nov 2026
1,5001,6001,7001,80018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Rubicon Research Limited

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Parag Suganchand Sancheti

Headquarters

Mumbai

Employees

1,290

Key stats

Market cap

₹28,856.78 Cr

P/E ratio (TTM)

100.4

Dividend yield

0.09%

EPS (TTM)

₹17.36

Beta (1Y · daily vs NIFTY 50)

0.41

Shares float

5.53 Cr

EPS · quarter ended Jun 2026

₹5.08

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0%5%10%15%FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY26

03 · Dividend Profile

0112₹0%0%0.1%0.1%0.1%07 Aug 26
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

0%20%40%60%FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.25×0.5×0.75×1×FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-250 Cr0 Cr250 Cr500 Cr₹FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY25FY26
₹1,267.10 Cr₹1,753.96 Cr
EBITDA
₹265.79 Cr₹407.96 Cr
—₹246.74 Cr
Diluted EPS
—₹15.31

Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Net income, Pretax income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹246.74 Cr while the annual report gives ₹188.17 Cr (23.7% apart).

EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹407.96 Cr while the annual report gives ₹321.49 Cr (21.2% apart).

09 · Balance Sheet

Annual

Line itemFY25FY26
₹1,451.43 Cr₹2,326.71 Cr
₹417.61 Cr₹311.01 Cr
Stockholders' equity
₹540.98 Cr₹1,288.82 Cr

Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY25FY26
—₹205.05 Cr
Investing cash flow
—₹-409.72 Cr
—₹283.07 Cr
Capital expenditure
—₹-229.17 Cr
End cash position
—₹185.65 Cr

Operating cash flow, Depreciation & amortization, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemOct 25–Dec 25(2Q)Mar 26Jun 26
Promoter59.99%59.86%59.76%
Public40.01%40.14%40.24%
Employee trusts0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Rubicon Research Limited₹28,274.08 Cr₹1,716.898.421.9419.1%0.24+36.6%+163.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

RUBICON

Rubicon to set up pharma plant in city

Lokmat Times · 8 days ago

RUBICON

Rubicon Research Merger Returned After Missing 90% Thresholds

Multibagg AI · 9 days ago